Companies / Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc.
Nasdaq: IKTCIK 1750149WILMINGTON, DE
Financials · FY2024
Ownership
139.5M shares outstanding · as of Aug 4, 2026
Ownership
| Insiders | 0.88% | 1,225,336 |
| Institutions | 81.96% | 114,366,917 |
| Public float | 17.16% | 23,943,647 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 6
View all →| Insider | % of shares | Shares |
|---|---|---|
Cabell ChristopherPresident & Head of R&D | 0.48% | 676,564 |
Aurentz VincentDirector | 0.37% | 510,596 |
Munshi AmitDirector | 0.03% | 38,176 |
Berman Dennis NDirector | — | — |
Iwicki Mark TCEOChief Executive Officer · Director | — | — |
McIntyre DavidChief Financial Officer | — | — |
Institutional holders 83
View all →| Holder | Value | % of shares |
|---|---|---|
| $26.69M | 9.33% | |
| $22.29M | 7.79% | |
| $17.68M | 6.18% | |
| $16.53M | 5.78% | |
| $15.77M | 5.57% | |
| $12.67M | 4.43% | |
| $11.99M | 4.19% | |
| $11.06M | 3.87% | |
| $9.98M | 4.26% | |
| $9.35M | 3.27% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Blackstone Inc 13F manager | New | — | $9.98M | +5.9M | 5,938,276 4.26% of shares | medium |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | — | $9.06M | +4.5M +135.00% | 7,768,057 5.57% of shares | medium |
| Q1 2026 as of | Perceptive Advisors LLC 13F manager | Trim | — | $-5.22M | -3.1M -57.30% | 2,315,000 1.66% of shares | medium |
| Q1 2026 as of | Millennium Management LLC 13F manager | Add | — | $4.63M | +2.8M +1623.92% | 2,928,077 2.10% of shares | low |
| Q2 2026 as of | State Street Corporation 13F manager | Add | — | $2.75M | +1.4M +244.08% | 1,909,101 1.37% of shares | low |
| Q1 2026 as of | Geode Capital Management, LLC 13F manager | Add | — | $1.75M | +1.0M +92.35% | 2,170,186 1.56% of shares | low |
| Q1 2026 as of | Two Sigma Investments, LP 13F manager | New | — | $1.42M | +848K | 847,611 0.61% of shares | low |
| Q1 2026 as of | AQR Capital Management, LLC 13F manager | New | — | $289.0K | +172K | 172,013 0.12% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Perceptive Advisors LLC | Passive13G/A | — |
| Nantahala Capital Management, LLC | Passive13G/A | — |
| Sands Capital Life Sciences Pulse Fund II, L.P. | Passive13G/A | — |
| Fairmount Funds Management LLC | Passive13G/A | — |
| ADAR1 Capital Management, LLC | Passive13G/A | — |
| Perceptive Advisors LLC | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| IKT | — | 45719W205 |